Lijia Ma
马丽佳
Lijia Ma is a scientist-entrepreneur in AI-powered gene editing therapeutics. She founded Westlake Genetech (西湖云谷智药) in February 2021 as a co-founder, while serving as a principal investigator (PI) at the School of Life Sciences at Westlake University . The company applies artificial intelligence to gene-editing therapy development, with a particular focus on AAV delivery challenges and in vivo CAR-T approaches . Per Gaorong Ventures' 2023 profile, her aim was to walk through the full pipeline of bringing AI into practical gene-editing treatment development .
AI-generated — may contain errors, please verify.
Coverage
Westlake Valley Intelligent Pharma: Cracking the AAV Delivery Challenge with AI, Entering the Super Track of In Vivo CAR-T — Gene Therapy's Moment in China | Gaorong Future
Chinese gene therapies have a real shot at genuine innovation — even leapfrogging the competition.
高榕创投·Ma Lijia of Westlake Yungu Intelligence Pharma: AI Knocks on the Door to a Cure for Gene-Editing Therapies | Gaorong Ventures
AI for Science in practice.
高榕创投·Medtech Entrepreneurship Is a "Game for the Brave": How to Sharpen Innovation, Product, and Organizational Capabilities | Ronghui
Discussing trends in medical technology innovation and upgrading R&D team organizational management.
高榕创投·Westlake Valley Intelligent Pharma Raises Tens of Millions of RMB in Angel Round, AI Powers Gene-Editing Therapeutics
Dedicated to establishing a complete, end-to-end pipeline for applying AI technology in gene therapy.
高榕创投·
